Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand. The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available in both RUO and GMP formats), and three Wnt/RSPO Agonist proteins.
These innovative proteins are specifically engineered using advanced AI-based design platforms and protein evolutionary workflows to enhance cellular therapy processes and research applications. The products feature improved functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability, leveraging generative AI trained on nearly five decades of proteomic leadership.
The new proteins are designed to address critical needs in cell culture performance and optimization, particularly in cellular therapy applications, stem cell research, organoid development, and regenerative medicine.
Positive
- Launch of new AI-engineered protein portfolio expanding product offerings
- Dual availability of FGF basic Heat Stable in both RUO and GMP formats, enabling research and therapeutic applications
- Products feature enhanced functionalities including improved stability and performance
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -2.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne's expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability.
"Our growing portfolio of designer proteins combine cutting-edge AI technology and innovative protein engineering," said Will Geist, President, Protein Sciences Segment. "This expanded portfolio empowers our customers with versatile, high-performance solutions to boost the production of immune cells and enhance regenerative medicine cell therapies. Bio-Techne remains committed to developing the tools and workflow solutions our customers need to advance innovative cell therapies in both clinical and research settings."
The new products include:
- IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion.
- Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications.
- FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research.
- Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine.
With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of our market leading R&D Systems branded portfolio of proteins. For more information about these AI Modified Proteins, visit our website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-rd-systems-ai-engineered-designer-protein-portfolio-to-advance-cell-therapy-and-regenerative-medicine-302347098.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.